Cargando…
The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet’s disease: a systematic review and meta-analysis
OBJECTIVE: To study the effectiveness of infliximab for the treatment of refractory central neuro-Behçet’s disease. METHODS: In this systematic review and meta-analysis, the research question was designed using the ‘Population, Intervention, Comparator, and Outcomes’ (PICO) model and the search meth...
Autores principales: | Mohammed, Reem Hamdy A, Woldeamanuel, Yohannes W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201531/ https://www.ncbi.nlm.nih.gov/pubmed/37203384 http://dx.doi.org/10.1177/03000605231169895 |
Ejemplares similares
-
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013) -
Anti-TNF-α agents for refractory intestinal Behçet’s disease: case series and meta-analysis
por: Zhan, Shukai, et al.
Publicado: (2022) -
Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022) -
Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα)
por: Cao, Brent L, et al.
Publicado: (2018) -
Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis
por: Yang, Seungwon, et al.
Publicado: (2021)